Kyverna Therapeutics Inc (KYTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.25-1.20%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KYTX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | |
|---|---|---|---|---|---|
| Operating Expenses & Income | |||||
| R&D Expenses | 115.3 | 133.7 | 112.5 | 49.9 | — |
| Operating Income | (158.9) | (169.8) | (142.6) | (62.4) | — |
| Earnings from Continuing Operations | |||||
| Interest Expense | — | 0.5 | 0.1 | — | — |
| Interest & Investment Income | 8.2 | 9.1 | 15.4 | 2.3 | — |
| Other Non-Operating Income / Expenses | 6.3 | 8.5 | 15.1 | 2.0 | — |
| Income Tax Expense | — | — | — | 0.0 | — |
| Net Income | |||||
| Net Income | (152.6) | (161.3) | (127.5) | (60.4) | — |
| Per Share | |||||
| Basic EPS | (2.51) | (3.64) | (3.33) | (89.61) | — |
| Diluted EPS | (2.51) | (3.64) | (3.33) | (89.61) | — |
| Basic Weighted Avg Shares | 60.9 | 44.3 | 38.3 | 0.7 | — |
| Diluted Weighted Avg Shares | 60.9 | 44.3 | 38.3 | 0.7 | — |
| Supplemental | |||||
| EBITDA | — | (168.0) | (140.5) | (60.7) | — |
| EBIT | (158.9) | (169.8) | (142.6) | (62.4) | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.